# Adaptive Biotechnologies Corp: overview

ADPT · Nasdaq · CIK 1478320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adpt.md) · [Financials](/companies/adpt/financials.md) · [Filings](/companies/adpt/filings.md) · [Insiders](/companies/adpt/insiders.md)

Latest reported revenue: [$71.6m](/filings/0001193125-26-332940.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-332940).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [46.4](/filings/0001193125-25-267061.md) | [47.5 d](/filings/0001193125-26-076902.md) | [52.4](/filings/0001193125-26-206546.md) | [58.9](/filings/0001193125-26-332940.md) | [94.0](/filings/0001193125-25-267061.md) | [71.7 d](/filings/0001193125-26-076902.md) | [70.9](/filings/0001193125-26-206546.md) | [71.6](/filings/0001193125-26-332940.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(70.3%)](/filings/0001193125-25-267061.md) | [(71.3%) d](/filings/0001193125-26-076902.md) | [(56.4%)](/filings/0001193125-26-206546.md) | [(42.5%)](/filings/0001193125-26-332940.md) | [10.9%](/filings/0001193125-25-267061.md) | [(17.8%) d](/filings/0001193125-26-076902.md) | [(27.1%)](/filings/0001193125-26-206546.md) | [(22.0%)](/filings/0001193125-26-332940.md) |
| Net margin | % | [(69.1%)](/filings/0001193125-25-267061.md) | [(71.0%) d](/filings/0001193125-26-076902.md) | [(56.9%)](/filings/0001193125-26-206546.md) | [(43.5%)](/filings/0001193125-26-332940.md) | [10.2%](/filings/0001193125-25-267061.md) | [(18.9%) d](/filings/0001193125-26-076902.md) | [(28.3%)](/filings/0001193125-26-206546.md) | [(55.6%)](/filings/0001193125-26-332940.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001193125-25-267061.md) | not reported | [(0.20)](/filings/0001193125-26-206546.md) | [(0.17)](/filings/0001193125-26-332940.md) | [0.06](/filings/0001193125-25-267061.md) | not reported | [(0.13)](/filings/0001193125-26-206546.md) | [(0.25)](/filings/0001193125-26-332940.md) |
| Free cash flow | $m | [(27.4) d](/filings/0001193125-25-267061.md) | [(12.6) d](/filings/0001193125-26-076902.md) | [(29.7)](/filings/0001193125-26-206546.md) | [(13.1) d](/filings/0001193125-26-332940.md) | [(7.5) d](/filings/0001193125-25-267061.md) | [1.4 d](/filings/0001193125-26-076902.md) | [(10.3)](/filings/0001193125-26-206546.md) | [(7.6) d](/filings/0001193125-26-332940.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [154](/filings/0000950170-24-023095.md) | [185](/filings/0000950170-25-030913.md) | [170](/filings/0001193125-26-076902.md) | [179](/filings/0001193125-26-076902.md) | [277](/filings/0001193125-26-076902.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(135.4%)](/filings/0000950170-24-023095.md) | [(108.0%)](/filings/0000950170-25-030913.md) | [(133.3%)](/filings/0001193125-26-076902.md) | [(90.8%)](/filings/0001193125-26-076902.md) | [(20.6%)](/filings/0001193125-26-076902.md) |
| Net margin | % | [(134.3%)](/filings/0000950170-24-023095.md) | [(108.0%)](/filings/0000950170-25-030913.md) | [(132.3%)](/filings/0001193125-26-076902.md) | [(89.1%)](/filings/0001193125-26-076902.md) | [(21.5%)](/filings/0001193125-26-076902.md) |
| Diluted EPS | $ per share | [(1.48)](/filings/0000950170-24-023095.md) | [(1.40)](/filings/0000950170-25-030913.md) | [(1.56)](/filings/0001193125-26-076902.md) | [(1.08)](/filings/0001193125-26-076902.md) | [(0.39)](/filings/0001193125-26-076902.md) |
| Free cash flow | $m | [(254)](/filings/0000950170-24-023095.md) | [(200)](/filings/0000950170-25-030913.md) | [(167)](/filings/0001193125-26-076902.md) | [(98.9)](/filings/0001193125-26-076902.md) | [(48.9)](/filings/0001193125-26-076902.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/adpt/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-26 | [Rubinstein Julie](/insiders/1780664.md) | President and COO, Officer | Sale (S) | 3,378 | $26.30 | $88.8k | [Form 4](/filings/0001780664-26-000045.md) |
| 2026-10-26 | [Rubinstein Julie](/insiders/1780664.md) | President and COO, Officer | Sale (S) | 8,503 | $25.94 | $220.6k | [Form 4](/filings/0001780664-26-000045.md) |
| 2026-10-23 | [Rubinstein Julie](/insiders/1780664.md) | President and COO, Officer | Sale (S) | 7,381 | $25.28 | $186.6k | [Form 4](/filings/0001780664-26-000045.md) |
| 2026-10-23 | [Rubinstein Julie](/insiders/1780664.md) | President and COO, Officer | Sale (S) | 4,500 | $24.50 | $110.3k | [Form 4](/filings/0001780664-26-000045.md) |
| 2026-10-22 | [Rubinstein Julie](/insiders/1780664.md) | President and COO, Officer | Sale (S) | 1,700 | $25.29 | $43.0k | [Form 4](/filings/0001780664-26-000045.md) |
| 2026-10-22 | [Rubinstein Julie](/insiders/1780664.md) | President and COO, Officer | Sale (S) | 10,181 | $24.38 | $248.2k | [Form 4](/filings/0001780664-26-000045.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $643.4m | 29,993,708 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $324.7m | 15,139,159 |  | Added +1,836,134 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $137.4m | 6,403,587 |  | Added +309,443 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $126.8m | 5,911,366 |  | Added +2,053,944 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $117.5m | 5,476,231 |  | Added +984,757 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $99.2m | 4,625,859 |  | Added +2,660,249 |
| [WESTFIELD CAPITAL MANAGEMENT CO LP](/funds/1177719.md) | 2026-06-30 | $91.5m | 4,267,645 |  | Reduced −1,169,073 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $78.1m | 3,641,837 |  | Added +5,783 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $74.2m | 3,458,388 |  | Added +231,143 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $66.4m | 3,094,011 |  | Reduced −1,356,055 |

## Recent filings

[All 826 filings](/companies/adpt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 16:30 ET | [10-Q](/filings/0001193125-26-332940.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332940 |
| 2026-07-29 | 16:15 ET | [8-K](/filings/0001193125-26-323753.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-323753 |
| 2026-06-22 | 16:07 ET | [8-K](/filings/0001193125-26-277516.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-277516 |
| 2026-06-15 | 16:15 ET | [8-K](/filings/0001193125-26-271117.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-271117 |
| 2026-06-09 | 16:30 ET | [8-K](/filings/0001193125-26-263844.md) | 5.07 Shareholder vote results | 0001193125-26-263844 |
| 2026-05-05 | 16:30 ET | [10-Q](/filings/0001193125-26-206546.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206546 |
| 2026-05-05 | 16:15 ET | [8-K](/filings/0001193125-26-206455.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206455 |
| 2026-04-24 | 16:30 ET | [DEF 14A](/filings/0001193125-26-177409.md) | Proxy statement, period 2026-06-05 | 0001193125-26-177409 |
| 2026-02-26 | 16:31 ET | [10-K](/filings/0001193125-26-076902.md) | Annual report, period 2025-12-31 | 0001193125-26-076902 |
| 2026-02-05 | 16:15 ET | [8-K](/filings/0001193125-26-039409.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-039409 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076902.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/27cf227a-29b6-4df4-b98e-1461ba1fda48)

## About the filer

- CIK: 1478320
- Tickers: ADPT
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: WA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 19:53 ET. No prices; not investment advice.